The loop of innovation, from bench to bedside and back offers a promising alternative to the traditional linear model of translation from bench to bedside. By bridging the gap between basic science and clinical practice, researchers can translate discoveries into tangible benefits for patients. By embracing continuous feedback and iteration, this approach has the potential to revolutionize the way we develop and implement new treatments, leading to improved outcomes for patients and more efficient resource allocation in medical research.

Sustainability in healthcare goes beyond the conservation of environmental resources; it encompasses the durability and effectiveness of the healthcare system itself. For cancer researchers, this means not only developing novel therapies but also reimagining the entire patient care journey, from prevention and diagnosis to treatment and survivorship.

In the realm of modern medicine, a revolutionary approach is transforming the landscape of patient care: precision medicine. This groundbreaking concept is reshaping how we understand, diagnose, and treat diseases, offering a personalized approach that holds immense promise for improving patient outcomes.

Project Optimus, aims to address these challenges and develop new strategies to reevaluate dosing strategies and reform dose optimization of oncology drugs. This program shifts from the traditional approach to more of a dose-finding approach, considering both therapeutic effects and toxicity effects.

Project Livin’ Label is an educational initiative where using product labeling as a guide, the FDA’s Oncology Center of Excellence (OCE) will moderate the panel discussion - between a FDA reviewer, a clinical trial investigator, a patient who has used the therapy, and a representative from the company that developed the drug. Together, they delve into the journey of the oncology product from development to approval. 

Improving the success of clinical trials often begins with enhancements in preclinical trials. Here are several areas that can be addressed to enhance the transition from preclinical to clinical stages: